Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review

Pryor, Joseph B.; Weber, Bo R.; Weber, Jacob; Lockridge, Joseph B.; Olyaei, Ali J.

doi:10.1007/s40267-019-00646-4

Cited by 4 publications

(2 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on previous study results, both decrease triglycerides, serum total cholesterol and LDL-C levels after drug treatment significantly [13][14] . A three-months analysis exhibited that both rosuvastatin (10 mg) and rosuvastatin (5 mg) significantly decreased LDL-C and total cholesterol compared with patients treated with 10 mg atorvastatin 15 . Another 8-week study of 10 mg rosuvastatin treatment significantly decrease LDL-C and triglycerides in comparison to 10 mg atorvastatin [16][17] .…”

Section: Discussionmentioning

confidence: 97%

Comparison of Rosuvastatin Versus Atorvastatin on Lipid Lowering Effectiveness in Hyperlipidemic Patients

Atiq¹,

Rafique²,

Baig³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Hyperlipidaemia is the utmost important factors influencing coronary heart disease. Statins are supposed to be the 1st line of drug in clinical exercise for lowering low-density lipoprotein, total cholesterol and increasing HDL cholesterol. This study was held for the comparison of the safety and efficacy of atorvastatin and rosuvastatin in lowering hyperlipidaemia among hyperlipidemic patients. Study Design: A prospective observational study. Place and Duration: In the Medicine department of Mayo hospital, Lahore for three-months duration from 15th March 2021 to 15th June 2021. Methods: This study comprised 90 patients with newly diagnosed hyperlipidaemia divided into two groups containing equal number of patients in both. Patients prescribed 10 mg of atorvastatin in Group A and 5 mg of rosuvastatin in Group B once daily for 6 weeks by the treating doctor of medicine. The data was saved in a personalized proforma format, and the SPSS 20.0 was used for analysis. Results: Serum total cholesterol decreased significantly afterwards the treatment with the rosuvastatin and atorvastatin groups (p <0.00001, correspondingly), but no significant variance (p = 0.510) noticed among the both groups treated with statins. The decrease in serum triglycerides was also significant (p = 0.0006 in the rosuvastatin group and p = 0.042 in the atorvastatin group) but the comparable difference in lowering hyperlipidemia was no significant among the both groups (p = 0.309). Similarly, LDL-C serum levels were significantly reduced in both groups (p <0.00001) but no statistically significant variance (p = 0.756) noticed among the two groups in terms of efficacy. Conclusion: No substantial changes in serum HDL levels were observed. The difference among the both groups was not significant (p = 0.731). This analysis = shows that both rosuvastatin and atorvastatin improved the lipid profile, but no changes were seen significantly among the both groups. Keywords: Hyperlipidemia, Atorvastatin and Rosuvastatin.

show abstract

Section: Discussionmentioning

confidence: 97%

Comparison of Rosuvastatin Versus Atorvastatin on Lipid Lowering Effectiveness in Hyperlipidemic Patients

Atiq¹,

Rafique²,

Baig³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…Previous studies show that the decline in blood pressure is a strong risk factor in the decline of kidney function ( 19 , 20 ) and the use of antihypertensive medications may have accelerated kidney damage ( 21 ). Besides, cholesterol-lowering medication decreases the overall risk of cardiovascular disease (CVD) and mortality of patients with CKD ( 22 ). Hence, we included these medications in this study.…”

Section: Methodsmentioning

confidence: 99%

A Resampling Method to Improve the Prognostic Model of End-Stage Kidney Disease: A Better Strategy for Imbalanced Data

Shi

Pottelbergh

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundPrognostic models can help to identify patients at risk for end-stage kidney disease (ESKD) at an earlier stage to provide preventive medical interventions. Previous studies mostly applied the Cox proportional hazards model. The aim of this study is to present a resampling method, which can deal with imbalanced data structure for the prognostic model and help to improve predictive performance.MethodsThe electronic health records of patients with chronic kidney disease (CKD) older than 50 years during 2005–2015 collected from primary care in Belgium were used (n = 11,645). Both the Cox proportional hazards model and the logistic regression analysis were applied as reference model. Then, the resampling method, the Synthetic Minority Over-Sampling Technique-Edited Nearest Neighbor (SMOTE-ENN), was applied as a preprocessing procedure followed by the logistic regression analysis. The performance was evaluated by accuracy, the area under the curve (AUC), confusion matrix, and F3 score.ResultsThe C statistics for the Cox proportional hazards model was 0.807, while the AUC for the logistic regression analysis was 0.700, both on a comparable level to previous studies. With the model trained on the resampled set, 86.3% of patients with ESKD were correctly identified, although it was at the cost of the high misclassification rate of negative cases. The F3 score was 0.245, much higher than 0.043 for the logistic regression analysis and 0.022 for the Cox proportional hazards model.ConclusionThis study pointed out the imbalanced data structure and its effects on prediction accuracy, which were not thoroughly discussed in previous studies. We were able to identify patients with high risk for ESKD better from a clinical perspective by using the resampling method. But, it has the limitation of the high misclassification of negative cases. The technique can be widely used in other clinical topics when imbalanced data structure should be considered.

show abstract

Policosanol ameliorates renal inflammation and pyroptosis in hypercholesterolemic rabbits via modulation of HMGB1/PI3K/mTOR/NLRP3/Caspase-1 pathway

Elnagar

Elseweidy

Elkomy

et al. 2022

Journal of Functional Foods

View full text Add to dashboard Cite

Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review

Cited by 4 publications

References 89 publications

Comparison of Rosuvastatin Versus Atorvastatin on Lipid Lowering Effectiveness in Hyperlipidemic Patients

Comparison of Rosuvastatin Versus Atorvastatin on Lipid Lowering Effectiveness in Hyperlipidemic Patients

A Resampling Method to Improve the Prognostic Model of End-Stage Kidney Disease: A Better Strategy for Imbalanced Data

Policosanol ameliorates renal inflammation and pyroptosis in hypercholesterolemic rabbits via modulation of HMGB1/PI3K/mTOR/NLRP3/Caspase-1 pathway

Contact Info

Product

Resources

About